All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia - PubMed
4 hours ago
- #AML treatment
- #clinical trial
- #oral chemotherapy
- The study presents an all-oral treatment regimen for newly diagnosed AML in patients aged 75+ or ineligible for intensive chemotherapy.
- Oral decitabine-cedazuridine combined with oral venetoclax was tested and showed no drug-drug interactions.
- In phase 2b, 47% of patients achieved a complete response, and median overall survival was 15.5 months.
- Common grade 3+ adverse events included anemia (30%), neutropenia (26%), and febrile neutropenia (25%).
- The treatment offers an alternative to parenteral therapies, reducing patient and provider burdens.